The wait is over! Join PCCA Director of Research & Development Daniel Banov, RPh, to learn the science behind our newest base – SubMagna™ SL HMW.

Developed to provide an alternative dosing delivery system for commercially available semaglutide, tirzepatide and a broad range of other APIs, this base offers even more opportunities for compounders!

The anhydrous, self-emulsifying sublingual suspension vehicle provides the opportunity to circumvent gastrointestinal factors that can influence the bioavailability of APIs. Its permeation-enhancing and unique mucoadhesive properties help drive molecules into mucosal tissue, potentially driving greater drug absorption and offering increased API-to-tissue contact time.